Report: Friday, August 7, 2026, before the market opens
Conference call: 10:00 a.m. ET
Share price: $141.41 as of August 6
Vistra enters the quarter with a relatively favorable operating backdrop but a more demanding strategic checklist. The company produced record first-quarter adjusted EBITDA, Texas experienced an unusually warm spring, and PJM capacity economics remain strong. At the same time, investors are waiting for tangible progress on the Cogentrix acquisition, incremental large-load contracts, and the conversion of Vistra’s growth pipeline into updated earnings guidance.
The stock has fallen approximately 12% year to date, versus a roughly 13% gain for the S&P 500, and is about 16% below its July 23 close. That lowers the immediate valuation hurdle, but it also signals skepticism around power-market curves, regulatory uncertainty and the timing of data-center-related earnings.
My base case: a solid quarter and reaffirmed organic guidance, with the stock reaction driven more by Cogentrix, contracting and 2027–2029 earnings commentary than by reported EPS.
| Metric | Current reference point |
|---|---|
| 2026 adjusted EBITDA guidance | $6.8B–$7.6B |
| 2026 adjusted FCF before growth guidance | $3.925B–$4.725B |
| 2027 adjusted EBITDA opportunity | $7.4B–$7.8B |
| Q1 2026 adjusted EBITDA | $1.494B |
| Q2 2025 adjusted EBITDA | $1.349B |
| 2026 generation hedged as of May 1 | 98% |
| 2027 generation hedged as of May 1 | 89% |
| Remaining repurchase authorization as of May 1 | ~$1.5B |
The existing guidance excludes Cogentrix and the Meta PPAs. Vistra previously said it expected to update guidance after Cogentrix closes. (investor.vistracorp.com)
Published EPS estimates vary substantially by data provider—from roughly $2.00 to $2.40 per share—and revenue estimates range from approximately $5.7 billion to $6.4 billion. That dispersion reinforces why adjusted EBITDA, cash flow and guidance are more useful than a narrow EPS comparison for this company. (tipranks.com)
I would frame a reasonable Q2 adjusted EBITDA outcome at approximately $1.5 billion–$1.7 billion, compared with $1.349 billion last year. That is not a published consensus estimate; it reflects:
Vistra’s Q1 adjusted EBITDA increased 20% year over year to $1.494 billion, driven by stronger realized energy and capacity prices and the Lotus assets, while mild Texas weather hurt retail. Management nevertheless left its wide $6.8 billion–$7.6 billion full-year range unchanged. (investor.vistracorp.com)
A simple reaffirmation should be expected. More important will be whether management:
Because 2026 generation was already 98% hedged as of May 1, reported results should be relatively insulated from short-term commodity-price movements. The downside is that unusually strong spot markets do not translate one-for-one into earnings upside.
Investor takeaway: a narrow EPS beat without stronger full-year commentary probably will not be enough. Evidence that the organic business is moving toward the upper half of EBITDA and FCF guidance would be more meaningful.
Texas recorded its warmest spring in NOAA’s 132-year record. ERCOT also set new April and June demand records, including 82,772 MW on June 18. (ercot.com)
That should be supportive for Vistra’s retail electricity volumes and generation utilization. The comparison is especially notable because retail EBITDA fell to just $68 million in Q1, versus $184 million a year earlier, due largely to mild Texas weather.
However, investors should not assume that higher demand automatically produces exceptional wholesale earnings:
The main operating questions are therefore:
Vistra agreed to acquire Cogentrix’s roughly 5,500 MW gas fleet for an approximately $4.0 billion net purchase price, equivalent to about 7.25 times expected 2027 adjusted EBITDA and $730/kW. The portfolio includes assets in PJM, ISO New England and ERCOT. Vistra expects mid-single-digit adjusted FCF-per-share accretion in 2027 and high-single-digit average accretion over 2027–2029. (investor.vistracorp.com)
The original closing target was mid-to-late 2026, and management said in May that the deal remained on track for the second half.
The call should clarify:
The implied 2027 EBITDA contribution from the stated purchase multiple is roughly $550 million. A delay would not necessarily damage the long-term thesis, but it would defer guidance accretion and could pressure sentiment.
The most constructive outcome: an imminent closing date accompanied by updated 2026 guidance and a materially higher 2027 EBITDA framework.
Vistra’s 20-year agreements with Meta cover 2,609 MW of carbon-free power and capacity from its PJM nuclear plants:
Vistra has quantified the eventual FCF impact as:
The company still has approximately 3.2 GW of nuclear capacity at Beaver Valley and Comanche Peak available for potential long-term contracts, in addition to gas-plant and new-build opportunities.
Management is unlikely to give precise timing on unfinished negotiations. Still, investors will listen closely for changes in language around:
A new contract would be the clearest upside catalyst, but continued confidence in an active pipeline may be sufficient if accompanied by concrete milestones.
Vistra cleared approximately 10.924 GW in PJM’s 2028/2029 capacity auction at $325/MW-day. That equates to approximately $1.30 billion of gross annual capacity revenue before plant costs and other adjustments. The prior 2026/2027 auction produced roughly $1.24 billion from 10.314 GW at $329.17/MW-day, so the higher cleared volume more than offset the modestly lower price. (pjm.com)
This is not a Q2 earnings item, but it reinforces several elements of the thesis:
The caveat is political and regulatory risk. Elevated capacity prices increase pressure for price caps, market redesign and special procurement mechanisms. Investors should distinguish between strong underlying market fundamentals and the portion of that value that Vistra will ultimately be permitted to capture.
As of May 1, Vistra had:
At the August 6 share price and approximately 337 million shares, Vistra’s market capitalization is around $47.7 billion. The midpoint of 2026 adjusted FCF before growth represents roughly a 9% yield on that equity value, although the measure is not identical to conventional free cash flow and precedes growth spending.
Watch for:
Buybacks are more accretive at the current share price than they were earlier in the year, but management may prioritize balance-sheet capacity until Cogentrix closes.
| Outcome | What it might look like |
|---|---|
| Bull case | EBITDA above ~$1.65B; upper-half or higher organic guidance; Cogentrix close imminent; constructive contract update |
| Base case | EBITDA around $1.5B–$1.6B; full-year guidance reaffirmed; Cogentrix remains on track; no new major contract |
| Bear case | EBITDA below ~$1.4B; operational issues; lower-half guidance language; Cogentrix delay or weaker contracting commentary |
The reported quarter should be supported by stronger Texas demand, Lotus contributions and favorable PJM capacity economics. But the earnings print itself is unlikely to settle the investment debate.
The three most important items are:
Given the stock’s decline, a clean quarter plus an on-time Cogentrix update could produce a favorable reaction. A simple EPS beat and unchanged guidance may receive a muted response, while acquisition delays or weak fleet performance would challenge the argument that Vistra’s recent pullback is primarily a valuation reset rather than a deterioration in fundamentals.